Biotech Unusual Volume: Aldeyra Therapeutics (NASDAQ:ALDX), Alcobra (NASDAQ:ADHD), Receptos (NASDAQ:RCPT), Celsus Therapeutics (NASDAQ:CLTX)

Aldeyra Therapeutics Inc (NASDAQ:ALDX) rallied to a new all-time high Thursday after Aegis Capital began coverage of the biotech company working to develop treatments for rare skin and eye diseases with a Buy rating. Aldeyra Therapeutics Inc (NASDAQ:ALDX) stock performance was 12.26% in last session and finished the day at $7.51. Traded volume was 134,905.00million shares in the last session and the average volume of … Continue reading Biotech Unusual Volume: Aldeyra Therapeutics (NASDAQ:ALDX), Alcobra (NASDAQ:ADHD), Receptos (NASDAQ:RCPT), Celsus Therapeutics (NASDAQ:CLTX)

Healthcare Stocks In News: Ultragenyx (NASDAQ:RARE), Flexion (NASDAQ:FLXN), Receptos Inc (NASDAQ:RCPT), Acorda Therapeutics (NASDAQ:ACOR), Aratana Therapeutics (NASDAQ:PETX)

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) is up over 16% today on news of the company’s initiation of phase-II trials for its lead drug candidate KRN23, which is a monoclonal antibody for X-linked Hypophosphatemia (XLH). Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) stock performance was 14.30% in last session and finished the day at $48.67. Traded volume was 435,645.00million shares in the last session and the average volume of the … Continue reading Healthcare Stocks In News: Ultragenyx (NASDAQ:RARE), Flexion (NASDAQ:FLXN), Receptos Inc (NASDAQ:RCPT), Acorda Therapeutics (NASDAQ:ACOR), Aratana Therapeutics (NASDAQ:PETX)

Biotech Decliners: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Relypsa Inc (NASDAQ:RLYP), Receptos Inc (NASDAQ:RCPT), TG Therapeutics, Inc. (NASDAQ:TGTX), Chimerix Inc (NASDAQ:CMRX)

On May 9, 2014, Amicus Therapeutics, Inc. (NASDAQ:FOLD) updated its Investor Presentation for the Migalastat Monotherapy Program (the “Presentation”). The Company’s Chief Financial Officer, William D. Baird III and the Company’s Chief Operating Officer, Bradley L. Campbell, will present some or all of this Presentation to various investors in the coming months. A copy of the presentation materials is attached hereto as Exhibit 99.1. Amicus … Continue reading Biotech Decliners: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Relypsa Inc (NASDAQ:RLYP), Receptos Inc (NASDAQ:RCPT), TG Therapeutics, Inc. (NASDAQ:TGTX), Chimerix Inc (NASDAQ:CMRX)